DaVita Venture Group

DaVita Venture Group, founded in 2020 and based in Denver, Colorado, serves as the investment arm of DaVita Inc. It focuses on building partnerships with healthcare innovators to enhance the lives of patients with kidney disease. The group aims to invest in, develop, and launch products and solutions that improve care for kidney disease and related conditions. DaVita Venture Group targets early-stage and later-stage companies in key areas, including digital health, pharmaceuticals, medical devices, and care delivery models. By leveraging technology and data, the firm seeks to transform healthcare delivery, expand access to care, and improve clinical outcomes while reducing costs within the healthcare system.

Amanda Kovach

Director, Partnerships and Corporate Development

10 past transactions

Pathalys Pharma

Series B in 2024
Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Dock Health

Seed Round in 2023
Dock Health is a Boston-based company that provides a HIPAA-compliant task management and collaboration platform specifically designed for the healthcare sector. Founded in 2016, Dock Health aims to address critical workflow challenges and inefficiencies faced by clinicians and their teams. By facilitating better communication and collaboration through a user-friendly and secure system, Dock Health strives to enhance patient care and ensure that essential tasks are completed effectively. The platform is suitable for healthcare teams of various sizes and specialties, empowering both clinical and administrative staff to work more efficiently within their organizations.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Pathalys Pharma

Series A in 2023
Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Pathalys Pharma

Seed Round in 2021
Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Heartbeat Health

Series B in 2021
Heartbeat Health, Inc. is a healthcare technology company based in New York that specializes in providing virtual cardiovascular disease prevention and management services. Founded in 2017, it offers a data-driven platform that enables real-time consultations between patients and cardiologists. Through its web-based services, Heartbeat Health facilitates secure communication, allowing patients to receive medical advice, treatment, and dietary consultations from healthcare professionals. The company's focus is on reducing cardiovascular risk and improving patient outcomes by promoting continuous engagement and monitoring of heart health. By leveraging technology, Heartbeat Health aims to enhance the quality of care for patients and support at-risk organizations in managing cardiovascular conditions more effectively.

Nephrosant

Series A in 2021
NephroSant is a diagnostic startup founded by physicians and supported by a team of scientists, engineers, and clinicians. The company focuses on developing a urine-based diagnostic tool that aims to predict and prevent the progression of kidney disease. This innovative tool allows for the quantitative measurement of biomarkers, facilitating the early detection and ongoing monitoring of kidney health. It is particularly beneficial for physicians, as it enables the noninvasive detection of acute rejection in kidney transplant patients, ultimately contributing to improved outcomes in kidney care.

SameSky Health

Series B in 2020
SameSky Health is a provider of multicultural engagement and navigation solutions tailored for health plans, providers, and states. The company specializes in connecting payers, providers, and health systems with diverse Medicare patient populations through a patient engagement platform. This platform offers integrated services that include multi-channel messaging, care navigation, and data insights and consultancy. By addressing the unique needs of culturally diverse populations, SameSky Health aims to enhance patient engagement, reduce unnecessary emergency room visits, and ultimately improve health outcomes and the quality of care provided.

Wellth

Series A in 2020
Wellth is a digital health company based in New York that aims to enhance treatment adherence among individuals with chronic conditions. By leveraging behavioral economics, Wellth addresses the barriers that hinder patients from forming healthy habits and effectively managing their diseases. The company operates a mobile application that provides targeted incentive plans, reminders, and information to motivate users to engage in preventive health behaviors. Its platform not only empowers consumers to improve their adherence to medication and care plans but also helps reduce preventable hospitalizations and healthcare costs. Wellth's approach includes proven outcomes demonstrated through randomized controlled trials, making it a valuable solution for insurers and healthcare providers seeking to improve population health. Through its user-friendly application, Wellth supports members in establishing sustainable healthy habits while generating cost savings for payors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.